BRAF antibody

Catalog No. ABIN7880047

The Mouse Monoclonal anti-BRAF antibody (Clone BRAF-1626) (ABIN7880047) specifically detects BRAF in IHC (p). The antibody is reactive with Human samples.

Quick Overview for BRAF antibody (ABIN7880047)

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This BRAF antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: BRAF-1626

Product Details anti-BRAF Antibody

Purpose: BRAF Antibody (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: A recombinant fragment of human HMG20B/BRAF protein was used as the immunogen for the BRAF antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the BRAF antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the BRAF antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for BRAF

Target: BRAF (B-Raf proto-oncogene, serine/threonine kinase (BRAF))

Alternative Name: BRAF

Background: The BRAF gene encodes a cytoplasmic serine-threonine kinase, which initiates the activation of the mitogen-activated protein kinase (MAPK) signalling pathway. The oncogenic mutations in the kinase region of BRAF gene result in constitutive activation of the MAPK signalling pathway, leading to increased cell proliferation, resistance to apoptosis and tumor progression. The most common of all activating BRAF mutations leads to a substitution of valine (V) to glutamic acid (E) at the position 600 of the amino acid sequence. The BRAF V600E mutation is an important predictive and prognostic biomarker. The BRAF V600E mutation is detected in approximately 8 % of all solid tumours, including 45 % of papillary thyroid carcinomas, 40-60 % of melanomas, 5-15 % of colorectal adenocarcinomas, 35 % of serous low grade and borderline ovarian carcinomas, 1-3 % of non-small cell lung cancers, and 5-7 % of cholangiocarcinomas. Furthermore, the BRAF V600E mutation is found in 100 % of hairy cell leukaemia, 54 % Erdheim-Chester disease, 38 % of Langerhans cell histocytoses and 60 % of pleomorphic xanthoastrocytomas.

UniProt: Q9P0W2

Pathways: MAPK Signaling, RTK Signaling, Neurotrophin Signaling Pathway, Ribonucleoprotein Complex Subunit Organization, Hepatitis C, Autophagy